Charles River Laboratories International, Inc. News Headlines

CRL 
$70.59
*  
1.80
2.62%
Get CRL Alerts
*Delayed - data as of Jan. 26, 2015  -  Find a broker to begin trading CRL now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Narrower Loss at Orexigen in Q3 - Analyst Blog
11/14/2013 9:06:40 AM - Zacks.com


Dynavax Reports In-Line Loss, Beats Rev - Analyst Blog
11/8/2013 12:00:01 PM - Zacks.com


Salix Misses On Q3 Earnings; To Buy Santarus - Analyst Blog
11/8/2013 11:06:08 AM - Zacks.com


Orexigen, Sanofi Ink Deal - Analyst Blog
11/7/2013 5:05:26 PM - Zacks.com


PAREXEL's Earnings in Line but Shares Tank - Analyst Blog
11/5/2013 2:00:01 PM - Zacks.com


MDAS Loses Despite Earnings Beat - Analyst Blog
11/4/2013 11:00:01 AM - Zacks.com


China Biotech In Review: 3 China In-Licensings and 1 Nixed Intra-China Deal
11/3/2013 3:38:00 AM - Seeking Alpha


Charles River Beats on Q3 Earnings - Analyst Blog
10/30/2013 10:33:34 AM - Zacks.com


Will Merck's (MRK) Earnings Streak End? - Analyst Blog
10/25/2013 5:07:06 PM - Zacks.com


Alimera Down on 3rd Iluvien CRL - Analyst Blog
10/21/2013 5:07:13 PM - Zacks.com


pSivida: Thoughts In The Aftermath Of The Complete Response Letter On Iluvien
10/20/2013 6:06:00 PM - Seeking Alpha


pSivida: Thoughts In The Aftermath Of The Complete Response Letter On Iluvien
10/20/2013 4:13:46 PM - SeekingAlpha


Dynavax Progresses with Heplisav - Analyst Blog
10/17/2013 1:06:56 PM - Zacks.com


Pipeline Progress at Dynavax - Analyst Blog
10/15/2013 10:46:35 AM - Zacks.com


MannKind Resubmits Afrezza NDA - Analyst Blog
10/15/2013 9:47:45 AM - Zacks.com


FDA Panel to Review Chelsea's Northera - Analyst Blog
10/14/2013 4:22:01 PM - Zacks.com


Update on Orexigen's Contrave - Analyst Blog
10/8/2013 10:44:45 AM - Zacks.com


Valeant's Jublia Approved in Canada - Analyst Blog
10/7/2013 2:25:01 PM - Zacks.com


Update on Progenics Pharma's Relistor - Analyst Blog
10/3/2013 6:06:10 PM - Zacks.com


Update on Anacor's Tavaborole - Analyst Blog
10/3/2013 3:45:01 PM - Zacks.com


More Data on Novo Nordisk's Tresiba - Analyst Blog
9/25/2013 4:10:01 PM - Zacks.com


Data on Dynavax' Heplisav - Analyst Blog
9/25/2013 11:00:01 AM - Zacks.com


Encouraging Data on Dapagliflozin - Analyst Blog
9/25/2013 10:17:53 AM - Zacks.com


United Therapeutics NDA Accepted - Analyst Blog
9/13/2013 10:40:01 AM - Zacks.com


Target Date for Endo Health's Aveed - Analyst Blog
9/9/2013 4:57:53 PM - Zacks.com